insights_auto
Why is NVAX up 2.97%?
Dive Deeperchevron_right
NVAX:NASDAQ
Novavax Inc
$10.41
arrow_upward
+2.97%(+0.30) 1D
$10.46
arrow_upward
+0.48% (+0.050)bedtimeAfter hours
Closed: Sep 21, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$10.38
High
$10.70
Low
$10.21
Mkt. cap
1.72B
Avg. vol.
5.34M
Volume
0.00
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
Open
$10.38
High
$10.70
Low
$10.21
Mkt. cap
1.72B
Avg. vol.
5.34M
Volume
0.00
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
The Globe and Mail
·
3 hours ago
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX)
News Corp
·
7 hours ago
Novavax Inc. stock outperforms competitors on strong trading day
AD HOC NEWS
·
1 day ago
Novavax stock gains as Q2 2026 revenue rises and vaccine focus deepens
Yahoo Finance
·
3 days ago
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com